Robert E. Kalb - Faculty Biosketch

Robert E. Kalb, MD

Adjunct Professor of Dermatology

Department: Dermatology

Contact information

Buffalo Medical Group
325 Essjay Road
Suite 210
Buffalo, NY 14221

Office: 716-630-1102
Fax: 716-633-6507

Education:
B.S. (Biochemistry, summa cum laude)
State University of New York at Buffalo, 1978.
M.D. (cum laude)
Downstate Medical Center, 1982.

Post-Graduate Training
Intern in Medicine, Cornell University Medical Center, Memorial Sloan Kettering Cancer Center, North Shore University Hospital, New York and Manhasset, NY, 1982-1983.
Resident in Dermatology, Columbia University, College of Physicians & Surgeons, New York, New York, 1983-1985.
Chief Resident in Dermatology, Columbia University, College of Physicians & Surgeons, New York, New York, 1985-1986.

Certifications
Dermatology, 1986.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Mogavero, A; Kalb, RE.: Darier's disease in Decision Support in Medicine. https://www.decisionsupportinmedicine.com. Anderson, B; Heymann, W;Hivnor, CM; Lessin, SR. (eds.). 2017.

Kalb, RE.: Pustular psoriasis: Management. UpToDate, Post TW 2016.

Kalb, RE.: Pustular psoriasis: Pathegonesis, clinical manifestations, and diagnosis. UpToDate, Psot TW 2016.

Devins, K; Kalb RE; Helm TN.: Leukemia Cutis. http://emedicine.medscape.com/article/1097702-overview 2015.

Helm, MF; White-Davis, C; Kalb, RE.: Painful Erythema and Edema of the Ears. JAMA Dermatology 151: 785-786, 2015.

Lebwohl, MG; Kavanaugh, A; Armstrong, AW; Van Voorhees, AS; Kalb, RE.: Patient perspectives on psoriasis management: US results of the population-based multinational assessment of psoriasis and psoriatic arthritis survey. Psoriasis Forum 20: 124-132, 2015.

Kalb, RE; Fiorentino, DF; Lebwohl, MG; Toole, J; Poulin, Y; Cohen, AD, et al.: Risk of Serious Infection with Biologic and Systematic Treatment of Psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology 151: 961-969, 2015.

Gottlieb, AB; Kalb, RE; Langley, RG; Krueger, GG; de Jonh, EM; Guenther, L, et al.: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systematic and biologic therapies. Journal of Drugs and Dermatology 13: 1441-1448, 2014.

Takeshita, J; Wang, S; Shin, D.B.; Callis Duffin, K; Krueger, G.G.; Kalb, R.E., et al.: Comparative Effectiveness of Less Commonly Used Systematic Monotherapies and Common Combination Therapies for moderate-to-Severe Psoriasis in the Clinical Setting. Journal of the American Academy of Dermatology 71: 1167-75, 2014.

Kalb, RE; Blauvelt, A; Sofen, HL; Chevrier, M; Amato, D; Calabro, S, et al.: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate to severe psoriasis and inadequate response to etanercept: Results from the PSUNRISE trial. Journal of Drugs and Dermatology 12: 874-880, 2013.